Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on August 05, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences' board, meeting on August 5, 2025, approved its unaudited Q1 FY26 standalone and consolidated financial results. Consolidated revenue from operations grew to ₹773.00 Cr from ₹719.72 Cr year-on-year (about 7% growth), while consolidated net profit jumped to ₹125.10 Cr from ₹89.55 Cr (about 40% growth). Standalone performance was even stronger, with revenue rising to ₹578.64 Cr from ₹456.69 Cr (~27% growth) and net profit surging to ₹99.99 Cr from ₹17.04 Cr. The auditor (Walker Chandiok & Co LLP) issued an unmodified limited review opinion with no qualifications. The company noted that prior period figures were restated following the final purchase price allocation for the Swiss Parenterals acquisition, and Q1 results include the recently acquired Eris Bionxt (formerly Chemman Labs), making them not strictly comparable to last year.
Strong profit growth and margin expansion are positive signals for shareholders, though part of the standalone profit jump reflects subsidiary-level shifts and acquisition mix. The auditor change (from Deloitte Haskins & Sells to Walker Chandiok) and restated prior numbers may need monitoring, but overall the quarter shows healthy operating performance.